Normal human mammary epithelial cells proliferate rapidly in the presence of elevated levels of the tumor suppressors p53 and p21WAF1/CIP1

Journal of Cell Science

Volumn 122, Issue 16, 2009, Pages 2989-2995

  Huschtscha, Lily I ^a,c   Moore, Jonathan D ^a,c   Noble, Jane R ^a,c   Campbell, Hamish G ^a,c   Royds, Janice A ^b   Braithwaite, Antony W ^a,b,c   Reddel, Roger R ^a,c  

^a CHILDREN'S MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Human mammary epithelial cells; Mdm2; Nutlin 3a; p21WAF1 CIP1; P53

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; NUTLIN 3; PROTEIN MDM2; PROTEIN P53; PROTEIN P60; CYCLIN DEPENDENT KINASE INHIBITOR 1A; MDM2 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; BREAST EPITHELIUM; CELL GROWTH; CELL PROLIFERATION; CELL STRESS; CONTROLLED STUDY; DNA DAMAGE; GENE EXPRESSION; GROWTH CURVE; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STEM CELL; BIOLOGICAL MODEL; CELL DIVISION; CYTOLOGY; EPITHELIUM CELL; GENETIC TRANSCRIPTION; GENETICS; MAMMARY GLAND; METABOLISM; PROTEIN PROCESSING; PROTEIN STABILITY;

CELL DIVISION; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA DAMAGE; EPITHELIAL CELLS; HUMANS; MAMMARY GLANDS, HUMAN; MODELS, BIOLOGICAL; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STABILITY; PROTO-ONCOGENE PROTEINS C-MDM2; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 70350010305     PISSN: 00219533     EISSN: None     Source Type: Journal    
DOI: 10.1242/jcs.044107     Document Type: Article

References (42)

1. Alcorta, D. A., Xiong, Y., Phelps, D., Hannon, G., Beach, D. and Barrett, J. C. (1996). Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. Proc. Natl. Acad. Sci. USA 93, 13742-13747.
2. Barrett, J. C., Annab, L. A., Alcorta, D., Preston, G., Vojta, P. and Yin, Y. (1994). Cellular senescence and cancer. Cold Spring Harb. Symp. Quant. Biol. 59, 411-418.
3. Bischof, O., Nacerddine, K. and Dejean, A. (2005). Human papillomavirus oncoprotein E7 targets the promyelocytic leukemia protein and circumvents cellular senescence via the Rb and p53 tumor suppressor pathways. Mol. Cell. Biol. 25, 1013-1024.
4. Braithwaite, A. W. and Edwards, S. J. (2003). The p53 Pathway, Cancer and Aging (ed. S. C. Kaul and R. Wadhwa), pp. 121-149. The Netherlands: Kluwer.
5. Braithwaite, A. W., Royds, J. A. and Jackson, P. (2005). The p53 story: layers of complexity. Carcinogenesis 26, 1161-1169.
6. Brenner, A. J., Stampfer, M. R. and Aldaz, C. M. (1998). Increased p16 expression with first senescence arrest in human mammary epithelial cells and extended growth capacity with p16 inactivation. Oncogene 17, 199-205.
7. Bueso-Ramos, C. E., Manshouri, T., Haidar, M. A., Yang, Y., McCown, P., Ordonez, N., Glassman, A., Sneige, N. and Albitar, M. (1996). Abnormal expression of MDM-2 in breast carcinomas. Breast Cancer Res. Treat. 37, 179-188.
8. D'Amico, M., Wu, X, Fu, M., Rao, M., Albanese, C., Russell, R. G., Lian, H., Bregman, D., White, M. A. and Pestell, R. G. (2004). The inhibitor of cyclin-dependent kinase 4a/alternative reading frame (INK4a/ ARF) locus encoded proteins p16INK4a and p19ARF repress cyclin D1 transcription through distinct cis elements. Cancer Res. 64, 4122-4130.
9. Delmolino, L., Band, H. and Band, V. (1993). Expression and stability of p53 protein in normal human mammary epithelial cells. Carcinogenesis 14, 827-832.
10. Duncan, E. L. and Reddel, R. R. (1997). Genetic changes associated with immortalization: a review. Biochemistry (Mosc.) 62, 1263-1274.
11. Foster, S. A., Wong, D. J, Barrett, M. T. and Galloway, D. A. (1998). Inactivation of p16 in human mammary epithelial cells by CpG island methylation. Mol. Cell. Biol 18, 1793-1801.
12. Gorgoulis, V. G., Zoumpourlis, V., Rassidakis, G. Z., Karameris, A., Rassidakis, A. N., Spandidos, D. A. and Kittas, C. (1996). A molecular and immunohistochemical study of the MDM2 protein isoforms and p53 gene product in bronchogenic carcinoma. J. Pathol. 180, 129-137.
13. Harris, S. L. and Levine, A. J. (2005). The p53 pathway: positive and negative feedback loops. Oncogene 24, 2899-2908.
14. Hinshelwood, R. A., Huschtscha, L. I., Melki, J., Stirzaker, C., Abdipranoto, A., Vissel, B., Ravasi, T., Wells, C. A., Hume, D. A., Reddel, R. & et al. (2007). Concordant epigenetic silencing of transforming growth factor-β signaling pathway genes occurs early in breast carcinogenesis. Cancer Res. 67, 11517-11527.
15. Hollstein, M., Sidransky, D., Vogelstein, B. and Harris, C. C. (1991). p53 mutations in human cancers. Science 253, 49-53.
16. ARF with Mdm2 inhibits ubiquitin ligase activity ofMdm2 for tumor suppressor p53. EMBO J. 18, 22-27.
17. INK4a and the control of cellular proliferative life span. Carcinogenesis 20, 921-926.
18. INK4 expression by methylation is associated with lifespan extension of human mammary epithelial cells. Cancer Res. 58, 3508-3512.
19. INK4a expression. Exp. Cell Res. 265, 125-134.
20. Jimenez, G. S., Khan, S. H., Stommel, J. M. and Wahl, G. M. (1999). p53 regulation by post-translational modification and nuclear retention in response to diverse stresses. Oncogene 18, 7656-7665.
21. Kubbutat, M. H., Jones, S. N. and Vousden, K. H. (1997). Regulation of p53 stability by Mdm2. Nature 387, 299-303.
22. Lahav, G., Rosenfeld, N., Sigal, A., Geva-Zatorsky, N., Levine, A. J., Elowitz, M. B. and Alon, U. (2004). Dynamics of the p53-Mdm2 feedback loop in individual cells. Nat. Genet. 36, 147-150.
23. Landers, J. E., Cassel, S. L. and George, D. L. (1997). Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein. Cancer Res. 57, 3562-3568.
24. Miyajima, K., Tamiya, S., Oda, Y., Adachi, T., Konomoto, T., Toyoshiba, H., Masuda, K. and Tsuneyoshi, M. (2001). Relative quantitation of p53 and MDM2 gene expression in leiomyosarcoma; real-time semi-quantitative reverse transcription-polymerase chain reaction. Cancer Lett. 164, 177-188.
25. Moll, U. M. and Petrenko, O. (2003). The MDM2-p53 interaction. Mol. Cancer Res. 1, 1001-1008.
26. Muntoni, A., Fleming, J., Gordon, K. E., Hunter, K., McGregor, F., Parkinson, E. K. and Harrison, P. R. (2003). Senescing oral dysplasias are not immortalized by ectopic expression of hTERT alone without other molecular changes, such as loss of INK4A and/or retinoic acid receptor-β: but p53 mutations are not neccessarily required. Oncogene 22, 7804-7808.
27. Ossovskaya, V. S., Mazo, I. A., Chernov, M. V., Chernova, O. B., Strezoska, Z., Kondratov, R., Stark, G. R., Chumakov, P. M. and Gudkov, A. V. (1996). Use of genetic suppressor elements to dissect distinct biological effects of separate p53 domains. Proc. Natl. Acad. Sci. USA 93, 10309-10314.
28. Pfaffl, M. W., Horgan, G. W. and Dempfle, L. (2002). Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 30, e36.
29. Pochampally, R., Fodera, B., Chen, L., Shao, W., Levine, E. A. and Chen, J. (1998). A 60 kd MDM2 isoform is produced by caspase cleavage in non-apoptotic tumor cells. Oncogene 17, 2629-2636.
30. Pochampally, R., Fodera, B., Chen, L., Lu, W. and Chen, J. (1999). Activation of an MDM2-specific caspase by p53 in the absence of apoptosis. J. Biol. Chem. 274, 15271-15277.
31. Ramirez, R. D., Herbert, B. S., Vaughan, M. B., Zou, Y., Gandia, K., Morales, C. P., Wright, W. E. and Shay, J. W. (2003). Bypass of telomere-dcpendent replicative senescence (M1) upon overexpression of Cdk4 in normal human epithelial cells. Oncogene 22, 433-444.
32. Reddel, R. R. (2000). The role of senescence and immortalization in carcinogenesis. Carcinogenesis 21, 477-484.
33. Sharpless, N. E. (2005). INK4a/ARF: a multifunctional tumor suppressor locus. Mutat. Res. 576, 22-38.
34. Smyth, C. M., Helmer, M. A., Dalla-Pozza, L. and Rowe, P. B. (1993). Flow cytometric DNA analyses of frozen samples from children's solid tumors. Pathology 25, 388-393.
35. Stampfer, M. R. (1985). Isolation and growth of human mammary epithelia] cells. J. Tissue Cult. Methods 9, 107-115.
36. Stampfer, M. R., Garbe, J., Nijjar, T., Wigington, D., Swisshelm, K. and Yaswen, P. (2003). Loss of p53 function accelerates acquisition of telomerase activity in indefinite lifespan human mammary epithelial cell lines. Oncogene 22, 5238-5251.
37. Takasaki, Y., Yamada, Y., Sugahara, K., Hayashi, T., Dateki, N., Harasawa, H., Kawabata, S., Soda, H., Ikeda, S., Tomonaga, M. et al. (2003). Interruption of p16 gene expression in adult T-cell leukaemia/ lymphoma: clinical correlation. Br. J. Haematol. 122, 253-259.
38. Toouli, C. D., Huschtscha, L. I., Neumann, A. A., Noble, J. R., Colgin, L. M., Hukku, B. and Reddel, R. R. (2002). Comparison of human mammary epithelial cells immortalized by simian virus 40 T-Antigen or by the telomerase catalytic subunit. Oncogene 21, 128-139.
39. Vassilev, L. T. (2004). Small-molecule antagonists of p53-MDM2 binding: research tools and potential therapeutics. Cell Cycle 3, 419-421.
40. Vojtesek, B. and Lane, D. P. (1993). Regulation of p53 protein expression in human breast cancer cell lines. J. Cell Sci. 105, 607-612.
41. Woods, D. B. and Vousden, K. H. (2001). Regulation of p53 function. Exp. Cell Res. 264, 56-66.
42. Zhang, J., Pickering, C. R., Holst, C. R., Gauthier, M. L. and Tlsty, T. D. (2006). p16INK4a modulates p53 in primary human mammary epithelial cells. Cancer Res. 66, 10325-10331.